

The TCRA Charitable Donation Plan

TCRA, our startup LLC, holds multiple US and international patents. TCRA has the potential to be worth \$300-350 billion if the clinical lab market adopts its technology. We plan to use 50% of that value to provide funding to save the lives of the 140,000 babies who die from Rh disease every year. This charitable work is already being done by WIRhE, an organization that disseminates a drug developed by the founder of TCI, Dr. John Gorman.

The TCRA charitable donation plan is possible due to the incredible need for technological advancement in the slow-moving clinical lab industry. If TCRA's patented DLA technology becomes the standard in the 50,000 globally operating labs, TCRA will have access to upwards of \$800 billion in royalty cash flow based on tapping \$8.8 trillion in the recurring total revenues clinical labs will earn over the next 20 years.

To achieve a valuation of \$300-350 billion, TCRA needs to be adopted by very big players. The initial impact for TCRA must come from the Big 4 clinical lab automation manufacturers: *Siemens, Abbott, Beckman Coulter, and Roche* ("*The Big 4*"). These clinical lab manufacturers have the collective power to catalyze a new global standard in lab technology by announcing an upgrade to DLA technology.

The Big 4 can be motivated to announce the adoption of DLA by 1) owning shares in TCI and 2) receiving royalty-free licenses to design and manufacture DLA analyzers. Since the building of new laboratories is funded by hospitals, medical centers, and companies such as Quest Diagnostics, the Big 4 have the potential to dramatically increase the value of their shares in TCI by simply announcing the adoption. We have budgeted upwards of 8% equity per Big 4 member. The remaining equity will be distributed between a charitable DAF (50%) and the current shareholders.

Patent royalties will be passed tax-free to TCRA to shareholders over the next 20 years. Just like a CDO, TCRA will bundle royalties from approximately 50,000 clinical labs worldwide into a single cash flow obligation to TCRA shareholders. Enforcement of royalty collection is ensured at the point of sale of each new DLA system: the Big 4 commit not to sell lab automation equipment to any clinical lab that has not signed a contract to pay the royalties. This simple measure will make royalty enforcement easy.

As an asset light patent holding company, TCRA does not need significant working capital to operate. All of the financial heavy lifting (the cost of labor, property, and project management) is managed separately by the Big 4 in alignment with their own business interests. TCRA margins have the potential to be more than 99% EBT.

TCI, Inc. Supporting Documents
TCRA Charitable Donation Plan

If we publicize the TCRA charitable donation plan it has the potential of motivating the Big 4 by allowing them to claim their role in funding WIRhE. A publication in a major news outlet such as The Wall Street Journal may be the best way to make Big 4 aware of not only the extraordinary business opportunity

The monetization of TCRA will result in the ultimate win-win. If we achieve our targets, there will be enough money to fund WIRhE – 140,000 Rh babies' lives will be saved annually in the developing world. Upwards of \$400 billion inc cash flow will go to charity and other public causes. DAF allocation ensures long-term philanthropic impact. Additional charitable giving may directed towards Inga 3, which will bring electricity to 600 million people in Africa. The Big 4 will be handsomely rewarded for both the economic and societal benefits brought about through their adoption of DLA. Clinical labs can look forward to much improved operations with DLA. With DLA, the FDA will be able to regulate labs in a much better way, resulting in more reliable lab test results in the future. DLA will be an ideal forum for essential LDT innovations. At TCI, we are excited and humbled by the tremendous amount of good that can be achieved through our innovation.